The FDA on Thursday approved Takeda’s recombinant ADAMTS13, now to be marketed as Adzynma, for the treatment of the rare blood disorder congenital thrombotic thrombocytopenic purpura—the biopharma company’s second approval in as many days.
Tag Archive for: genetic blood clotting disorder
Today the Dutch drug developer said it would sell a part of the royalty rights for the world’s most expensive treatment Hemgenix to HealthCare Royalty and Sagard Healthcare for up to $400 million in cash.
